3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
3
NET
2
Gastrointestinal
2
Sarcoma
1
CNS
1
Conditions
Brain Neoplasms
83
Glioma
73
Glioblastoma
73
Neuroblastoma
27
Neoplasms
22
Astrocytoma
20
Neurofibromatosis 1
19
Ependymoma
19
Sarcoma
18
Medulloblastoma
18
Central Nervous System Neoplasms
18
Rhabdoid Tumor
15
Melanoma
15
Meningioma
14
Carcinoma, Non-Small-Cell Lung
14
Osteosarcoma
13
Wilms Tumor
12
Sarcoma, Ewing
12
Rhabdomyosarcoma
12
Breast Neoplasms
12
Neurofibroma, Plexiform
11
Hepatoblastoma
11
Diffuse Intrinsic Pontine Glioma
10
Neuroectodermal Tumors, Primitive, Peripheral
9
Lymphoma, Non-Hodgkin
9
Histiocytosis, Langerhans-Cell
9
Thyroid Neoplasms
8
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
CNS
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA